InVitro International (IVRO)
USD 0.1
(15.93%)
USD 0.1
(15.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1553.00 USD | -92.7% |
| 2022 | 21.27 Thousand USD | -77.84% |
| 2021 | 95.99 Thousand USD | 92.39% |
| 2020 | 49.89 Thousand USD | -29.4% |
| 2019 | 70.67 Thousand USD | 25.29% |
| 2018 | 56.4 Thousand USD | 17.92% |
| 2017 | 47.83 Thousand USD | -61.08% |
| 2016 | 122.9 Thousand USD | -47.05% |
| 2015 | 232.1 Thousand USD | 753.75% |
| 2014 | 27.18 Thousand USD | 0.0% |
| 1996 | -1.9 Million USD | 32.14% |
| 1995 | -2.8 Million USD | 36.36% |
| 1994 | -4.4 Million USD | -18.92% |
| 1993 | -3.7 Million USD | 27.45% |
| 1992 | -5.1 Million USD | -45.71% |
| 1991 | -3.5 Million USD | -3600.0% |
| 1990 | 100 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 17.66 Thousand USD | -63.97% |
| 2024 Q2 | 47.67 Thousand USD | 169.87% |
| 2024 Q3 | 16.23 Thousand USD | -65.95% |
| 2023 Q2 | -3353.00 USD | 89.17% |
| 2023 Q4 | 49.03 Thousand USD | 472.55% |
| 2023 Q1 | -30.96 Thousand USD | -272.74% |
| 2023 Q3 | -13.16 Thousand USD | -292.54% |
| 2023 FY | 1553.00 USD | -92.7% |
| 2022 Q3 | -28.95 Thousand USD | -19.1% |
| 2022 FY | 21.27 Thousand USD | -77.84% |
| 2022 Q1 | 56.94 Thousand USD | 3357.44% |
| 2022 Q2 | -24.3 Thousand USD | -142.69% |
| 2022 Q4 | 17.92 Thousand USD | 161.92% |
| 2021 Q2 | -57.56 Thousand USD | 0.0% |
| 2021 FY | 95.99 Thousand USD | 92.39% |
| 2021 Q4 | -1748.00 USD | -101.99% |
| 2021 Q3 | 87.64 Thousand USD | 252.25% |
| 2020 FY | 49.89 Thousand USD | -29.4% |
| 2019 FY | 70.67 Thousand USD | 25.29% |
| 2018 FY | 56.4 Thousand USD | 17.92% |
| 2017 FY | 47.83 Thousand USD | -61.08% |
| 2016 FY | 122.9 Thousand USD | -47.05% |
| 2015 FY | 232.1 Thousand USD | 753.75% |
| 2014 FY | 27.18 Thousand USD | 0.0% |
| 1997 Q2 | -1.2 Million USD | -140.2% |
| 1997 Q3 | -195 Thousand USD | 83.76% |
| 1997 Q1 | -500 Thousand USD | 16.67% |
| 1996 Q3 | -300 Thousand USD | 40.0% |
| 1996 Q4 | -600 Thousand USD | -100.0% |
| 1996 Q1 | -500 Thousand USD | 37.5% |
| 1996 Q2 | -500 Thousand USD | 0.0% |
| 1996 FY | -1.9 Million USD | 32.14% |
| 1995 Q2 | -700 Thousand USD | 0.0% |
| 1995 FY | -2.8 Million USD | 36.36% |
| 1995 Q4 | -800 Thousand USD | -33.33% |
| 1995 Q3 | -600 Thousand USD | 14.29% |
| 1995 Q1 | -700 Thousand USD | 46.15% |
| 1994 Q4 | -1.3 Million USD | -18.18% |
| 1994 Q1 | -1 Million USD | 16.67% |
| 1994 Q2 | -1 Million USD | 0.0% |
| 1994 Q3 | -1.1 Million USD | -10.0% |
| 1994 FY | -4.4 Million USD | -18.92% |
| 1993 Q1 | -700 Thousand USD | 53.33% |
| 1993 Q3 | -700 Thousand USD | 30.0% |
| 1993 Q4 | -1.2 Million USD | -71.43% |
| 1993 FY | -3.7 Million USD | 27.45% |
| 1993 Q2 | -1 Million USD | -42.86% |
| 1992 Q2 | -1.3 Million USD | -44.44% |
| 1992 FY | -5.1 Million USD | -45.71% |
| 1992 Q4 | -1.5 Million USD | 0.0% |
| 1992 Q3 | -1.5 Million USD | -15.38% |
| 1992 Q1 | -900 Thousand USD | -28.57% |
| 1991 Q3 | -500 Thousand USD | 0.0% |
| 1991 FY | -3.5 Million USD | -3600.0% |
| 1991 Q4 | -700 Thousand USD | -40.0% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 FY | 100 Thousand USD | 0.0% |
| 1990 Q1 | - USD | 100.0% |
| 1990 Q3 | 100 Thousand USD | 0.0% |
| 1990 Q4 | - USD | -100.0% |
| 1989 Q3 | -100 Thousand USD | 0.0% |
| 1989 Q4 | -100 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | 100.11% |
| Arrayit Corporation | -3.31 Million USD | 100.047% |
| Atlantic International Corp. | -5.62 Million USD | 100.028% |
| Biocept, Inc. | -32.08 Million USD | 100.005% |
| Bioqual, Inc. | 483.48 Thousand USD | 99.679% |
| CardioGenics Holdings Inc | -1.91 Million USD | 100.081% |
| DermTech, Inc. | -100.88 Million USD | 100.002% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 100.0% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 100.007% |
| iMD Companies, Inc. | -200.63 Thousand USD | 100.774% |
| IDenta Corp. | 14.64 Thousand USD | 89.395% |
| Interpace Biosciences, Inc. | 802 Thousand USD | 99.806% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | 95.986% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 100.018% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 102.672% |
| Medical Imaging Corp. | -3.02 Million USD | 100.051% |
| NovelStem International Corp. | -4.18 Million USD | 100.037% |
| Optigenex Inc. | -2.89 Million USD | 100.054% |
| PharmChem, Inc. | 845.1 Thousand USD | 99.816% |
| Proteome Sciences plc | -2.44 Million USD | 100.064% |
| Response Genetics, Inc | -20.18 Million USD | 100.008% |
| Rennova Health, Inc. | -3.29 Million USD | 100.047% |
| RushNet, Inc. | -607.02 Thousand USD | 100.256% |
| ScreenPro Security Inc. | -2.24 Million USD | 100.069% |
| Stella Diagnostics Inc. | -5.7 Million USD | 100.027% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 100.014% |
| Todos Medical Ltd. | -24.99 Million USD | 100.006% |